Who is sponsoring NCT00765817?

NCT00765817 is sponsored by AstraZeneca.

What condition does NCT00765817 study?

NCT00765817 studies Type 2 Diabetes.

What drugs are being tested in NCT00765817?

Interventions: placebo, exenatide.

What is the status of NCT00765817?

NCT00765817 is currently COMPLETED.

Last reviewed 2016-10-21 · How we verify

A Randomized Trial Comparing Exenatide With Placebo in Subjects With Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications

NCT00765817 Phase 3 COMPLETED Results posted

This study will compare the efficacy and safety of exenatide versus placebo in adults whose diabetes is not fully controlled by insulin glargine with or without metformin and/or pioglitazone.

Details

Lead sponsor	AstraZeneca
Phase	Phase 3
Status	COMPLETED
Enrolment	261
Start date	2008-10
Completion	2010-01

Conditions

Type 2 Diabetes

Interventions

placebo
exenatide

Primary outcomes

Change in Glycosylated Hemoglobin (HbA1c) — baseline and 30 weeks
Change in HbA1c from baseline following 30 weeks of therapy (i.e., HbA1c at week 30 minus HbA1c at baseline). Unit of measure is percent of hemoglobin that is glycosylated.

Countries

United States, Greece, Israel, Mexico, Puerto Rico, United Kingdom